Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Sarcoma 1Neuroblastoma 1Lymphoma 1Leukemia 1Central Nervous System Neoplasms 1

Interventions

Filgrastim 4Cyclophosphamide 4Psychiatric Rehabilitation 3Palliative Care 3Busulfan 3aflibercept 2Vincristine 2Thalidomide 2Radiotherapy 2Paclitaxel 2Melphalan 2Leucovorin 2Irinotecan 2Gemcitabine 2Etoposide 2Doxorubicin 2Docetaxel 2Celecoxib 2Azacitidine 2Analgesia 2venetoclax 1trimetrexate glucuronate 1tazemetostat 1tanespimycin 1sargramostim 1romidepsin 1ripretinib 1pembrolizumab 1liposomal doxorubicin 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Fenofibrate × Other hematologic neoplasm × Clear all
NCT00357500 2014-10-01

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
101 enrolled 10 charts
CNSLymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡